Mary Schaefer, MD
Anesthesiology · Kailua, HINPI 1770511503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 546 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2021 at $2,584 and has fallen 69.2% since, to $795 in 2025. Among anesthesiology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Pfizer$1K
- Biohaven Pharmaceuticals, Inc.$733
- Novo Nordisk$691
- plus $3K from 18 others
What the payments were for
- Food & beverage$10,75299%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $3,084 |
| Amgen(2 entities) | 57 | $1,314 |
| Teva Pharmaceuticals USA, Inc. | 70 | $1,205 |
| Pfizer | 69 | $1,035 |
| Biohaven Pharmaceuticals, Inc. | 35 | $733 |
| Novo Nordisk | 36 | $691 |
| Biohaven Pharmaceutical Holding Company Ltd. | 32 | $587 |
| Eisai Inc. | 19 | $461 |
| Galt Pharmaceuticals, LLC | 1 | $334 |
| Revance Therapeutics, Inc. | 8 | $247 |
| Lilly USA, LLC | 7 | $181 |
| Idorsia Pharmaceuticals US Inc | 7 | $153 |
| Medtronic(2 entities) | 7 | $150 |
| Supernus Pharmaceuticals, Inc. | 7 | $117 |
| Lundbeck LLC | 4 | $106 |
| Upsher-smith Laboratories LLC | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Merck | 4 | $64 |
| Boston Scientific | 3 | $50 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Vertex | 2 | $47 |
| Novartis | 3 | $41 |
| Merz North America, Inc. | 1 | $35 |
| LEO Pharma Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orphengesic Forte$334
- NURTEC ODT$125
- QULIPTA$125
- UBRELVY$125
- KRYSTEXXA$125
- Dayvigo$123
- Repatha$116
- DAXXIFY$112
- AJOVY$110
How this compares
$10,874 in reported general payments places this provider in the 95th percentile of 186 anesthesiology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 45 | $59,270 |
| OxycontinOxycodone Hcl | 28 | $39,327 |
| Xtampza ErOxycodone Myristate | 22 | $29,342 |
| UbrelvyUbrogepant | 18 | $20,138 |
| Nurtec OdtRimegepant Sulfate | 12 | $17,516 |
| AdderallDextroamphetamine/Amphetamine | 12 | $10,890 |
| MovantikNaloxegol Oxalate | 12 | $7,473 |
| Oxycodone Hcl | 137 | $5,963 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 82 | $2,170 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $1,268 |
| Methadone Hcl | 24 | $1,253 |
| Fentanyl | 13 | $1,151 |
| Lubiprostone | 13 | $1,059 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 21 | $774 |
| Morphine Sulfate | 22 | $760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy | $3,084 | $79,40963 claims |
| PfizerNurtec Odt | $1,035 | $17,51612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $74 | $10,89012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 186 anesthesiology providers in Hawaii.
Other anesthesiology in Kailua
- Josianna HensonKahului$18K
- William RheeKealakekua$9K
- Clifford CharHonolulu$6K
- Oren BernsteinHonolulu$3K
- Thomas SanchezLihue$3K
- Carl HoHonolulu$3K
- Nicole MorikawaHonolulu$2K
- Adam AritaHonolulu$2K
- Tiffany ChingHonolulu$2K
- Joshua RismanyKahului$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.